Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDyadic International Inc

Dyadic International Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3398 USD -0.00 ( 0.09%)
Last update at 2026-11-06T21:00:00Z
VOLUME
66995
Market Cap
17.14M

Momentum Score

…

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.35
High
52 Week Price Range
0.35
Low
1.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Dyadic International develops and licenses a proprietary C1 fungal-based protein expression platform used to produce enzymes and biologics for pharmaceutical, industrial and research customers. Long-term growth may benefit from wider adoption of the C1 platform, more licensing and service agreements, and regulatory acceptance; investors may find the company attractive for its technology focus and potential recurring partner revenue.
Investors should monitor limited commercial traction, competition from established expression systems, manufacturing and scale-up risks, regulatory hurdles for platform-derived biologics, and potential need for additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.34
Dividend Yield
-
Revenue TTM
3.80M
Revenue Per Share
0.11
Gross Profit TTM
0.62M
Debt / Equity
4.11
ROE
-2826.92%
Net Debt
0.44M
ROCE
-114.18%
Diluted EPS TTM
-0.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.36M -5.81M -6.80M -9.74M -13.07M
Net income -7.36M -5.81M -6.80M -9.37M -12.92M
Selling general administrative 5.76M 6.13M 5.82M 6.42M 6.70M
Gross profit 0.77M 2.30M 0.92M 0.81M 0.46M
Ebit - -11.26M -8.19M -10.12M -14.73M
Ebitda -7.15M -5.38M -8.15M -10.07M -16.14M
Depreciation and amortization - 5.88M 0.04M 0.05M -1.41M
Operating income -7.15M -5.90M -8.23M -10.12M -14.73M
Other operating expenses 10.28M 9.40M 11.13M 13.05M 17.03M
Interest expense 0.46M 0.43M 0.00M -0.38M 0.05M
Tax provision - - - - 0.00M
Interest income 0.28M 0.46M 0.42M 0.18M 0.05M
Net interest income -0.17M 0.03M 0.42M 0.18M 0.05M
Income tax expense - -5.81M -8.19M -0.36M -0.15M
Total revenue 3.09M 3.50M 2.90M 2.93M 2.40M
Total operating expenses 7.92M 8.20M 9.15M 10.92M 15.09M
Cost of revenue 2.32M 1.19M 1.98M 2.12M 1.94M
Total other income expense net -0.22M 0.09M 1.43M 0.38M 1.66M
Net income from continuing ops -7.36M -5.81M -6.80M -9.74M -13.07M
Net income applicable to common shares - - - -9.74M -13.07M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.95M 9.93M 8.22M 13.71M 21.30M
Other current assets 1.45M 0.33M 0.33M 0.39M 0.38M
Total liab 8.71M 7.46M 2.34M 2.63M 2.91M
Total stockholder equity 1.23M 2.47M 5.88M 11.09M 18.39M
Other current liab 2.80M 1.91M 1.14M 1.00M 0.86M
Common stock 0.05M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.04M 0.04M 0.04M 0.04M
Retained earnings -93.45M -86.09M -80.28M -73.48M -63.75M
Other liab - - - 0.18M 0.35M
Other assets - - - 0.01M 0.01M
Cash 4.62M 6.51M 6.52M 5.79M 15.75M
Total current liabilities 3.69M 2.45M 2.25M 2.45M 2.56M
Current deferred revenue - - 0.49M 0.18M 0.15M
Net debt 0.44M -1.44M -6.38M -5.79M -15.75M
Short term debt 0.03M 0.05M 0.05M - -
Short long term debt total 5.06M 5.07M 0.14M - -
Other stockholder equity 94.64M 88.51M 86.11M 84.53M 82.10M
Total current assets 9.90M 9.83M 8.07M 13.42M 21.01M
Long term investments - - 0.00M 0.28M 0.28M
Net tangible assets - - - 11.09M 18.39M
Short term investments 2.70M 2.76M 0.75M 6.85M 4.51M
Net receivables 1.13M 0.24M 0.48M 0.39M 0.37M
Long term debt 5.03M 4.98M - - -
Inventory - - 0.00M - -
Accounts payable 0.85M 0.48M 0.58M 1.28M 1.55M
Accumulated other comprehensive income - 0.00M 0.00M - -
Non currrent assets other 0.01M 0.01M 0.01M 0.01M 0.01M
Non current assets total 0.05M 0.10M 0.15M 0.29M 0.29M
Capital lease obligations 0.03M 0.09M 0.14M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.08M -1.88M 7.45M -2.37M 5.22M
Change to liabilities - - - -0.51M 1.08M
Total cashflows from investing activities 0.08M -1.88M 7.45M -2.37M 5.22M
Net borrowings 0.00M 5.82M 0.00M - -
Total cash from financing activities 4.96M 5.85M 0.00M 0.54M 1.23M
Change to operating activities - - - 0.27M 0.14M
Net income -7.36M -5.81M -6.80M -9.74M -13.07M
Change in cash -0.65M -0.01M 0.72M -9.95M -4.89M
Begin period cash flow 6.51M 6.52M 5.79M 15.75M 20.64M
End period cash flow 5.85M 6.51M 6.52M 5.79M 15.75M
Total cash from operating activities -5.70M -3.97M -6.73M -8.08M -11.28M
Issuance of capital stock 4.94M 0.00M - - -
Depreciation -0.02M -0.07M -0.05M 0.03M 0.33M
Change to inventory - - - - 0.14M
Change to account receivables -0.86M 0.21M -0.09M -0.08M -0.03M
Other cashflows from financing activities 4.96M 0.02M 7.45M 0.54M 1.23M
Change to netincome - - - 1.97M 0.61M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.66M 0.75M -0.14M -0.32M 1.19M
Stock based compensation 0.93M 1.13M 1.24M 1.89M 1.78M
Other non cash items 0.10M -0.05M -1.03M 0.05M -1.18M
Free cash flow -5.70M -3.97M -6.73M -8.08M -11.28M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DYAI
Dyadic International Inc		 -0.00
0.09%		 0.34 - 15.82 4.51 21.01 14.20 -2.93
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Dyadic International Inc

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094

561 743 8333

https://www.dyadic.com

5

Name Title Year Born
Mr. Mark A. Emalfarb Founder, CEO, Pres & Director 1956
Ms. Ping Wang Rawson CPA, M.B.A. Chief Financial Officer 1976
Mr. Joseph P. Hazelton Chief Bus. Officer NA
Dr. Ronen Tchelet Ph.D. VP of Research & Bus. Devel. 1958
Ms. Ana Gómez Rodriguez Sec. of the Board NA
Mr. Mark A. Emalfarb Founder, CEO, President & Director 1956
Mr. Joseph P. Hazelton Chief Business Officer NA
Mr. Doug Pace B.A. Executive Vice President of Business Development NA
Ms. Ana Gómez Rodriguez Secretary of the Board NA
Mr. Mark A. Emalfarb Founder, CEO & Director 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…